- Home
- CRBP vs PMI Comparison
CRBP vs PMI Comparison
Compare CRBP & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | PMI |
|---|---|---|
| Founded | 2009 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 202.7M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRBP | PMI |
|---|---|---|
| Price | $7.86 | $1.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $50.29 | N/A |
| AVG Volume (30 Days) | 492.2K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,767,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.81 |
| 52 Week Low | $4.64 | $1.65 |
| 52 Week High | $20.56 | $13.68 |
Technical Indicators
Market Signals| Indicator | CRBP | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | N/A |
| Support Level | $7.97 | N/A |
| Resistance Level | $8.54 | N/A |
| Average True Range (ATR) | 0.47 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 5.21 | 0.00 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.